Flight Centre Travel Group Ltd. logo

Flight Centre Travel Group Ltd. (AU000000FLT9)

Market Open
11 Jun, 06:09
XSTU XSTU
7. 50
0
0%
- Market Cap
21.74 P/E Ratio
0% Div Yield
0 Volume
16.96 Eps
7.5
Previous Close
Day Range
7.5 7.5
Year Range
6.5 14

Summary

AU000000FLT9 trading today higher at €7.5, an increase of 0% from yesterday's close, completing a monthly increase of 2.04% or €0.15. Over the past 12 months, AU000000FLT9 stock lost -24.24%.
AU000000FLT9 is not paying dividends to its shareholders.
The last earnings report, released on Feb 05, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on NYSE (USD).
Want to track AU000000FLT9 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

AU000000FLT9 Chart

Chart

Empty chart
The chart has 2 Y axes displaying values, and values.
Loading, please wait...
End of interactive chart.
Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia

Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia

Ongoing progress in Phase 1 clinical trial of SENTI-202 for the treatment of Acute Myeloid Leukemia (AML) 20,800 newly diagnosed AML patients in the U.S. every year 1 with 60% of patients experiencing relapse or death within 12 months 2 Management releases Virtual Investor “What This Means” segment; Access here SOUTH SAN FRANCISCO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML.

Globenewswire | 2 hours ago
Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025

New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib

Globenewswire | 5 days ago
Volatus Releases Q1 2025 Financial Results

Volatus Releases Q1 2025 Financial Results

Generated revenue of $5,713,158 in Q1 2025 Achieved 30% EBITDA improvement over Q1 2024 Continuation of optimization efforts post Volatus and Drone Delivery Canada merger of equals Subsequent to quarter end, closed $3,000,000 fully subscribed LIFE Offering Subsequent to quarter end, announced closing of shares for debt transaction of $2,646,000 and an additional $446,400, strengthening balance sheet Volatus will host a webinar and live Q&A on Monday, June 2, 2025, at 8 am ET (see registration link below). TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV:FLT) (OTCQB:TAKOF) (Frankfurt:A3DP5Y/ABBA.F) ("Volatus" or "the Company"), a leader in aerial solutions, is pleased to announce its financial results for the three months ended March 31, 2025 (Q1 2025).

Globenewswire | 2 weeks ago

Flight Centre Travel Group Ltd. Dividends

AU000000FLT9 is not paying dividends to its shareholders.

Flight Centre Travel Group Ltd. Earnings

5 Feb 2025 Date
-
Cons. EPS
-
EPS
6 Nov 2024 Date
-
Cons. EPS
-
EPS
6 Aug 2024 Date
-
Cons. EPS
-
EPS
1 May 2024 Date
4.1
Cons. EPS
-
EPS
7 Feb 2024 Date
4.48
Cons. EPS
4.44
EPS
AU000000FLT9 is not paying dividends to its shareholders.
5 Feb 2025 Date
-
Cons. EPS
-
EPS
6 Nov 2024 Date
-
Cons. EPS
-
EPS
6 Aug 2024 Date
-
Cons. EPS
-
EPS
1 May 2024 Date
4.1
Cons. EPS
-
EPS
7 Feb 2024 Date
4.48
Cons. EPS
4.44
EPS

Flight Centre Travel Group Ltd. (AU000000FLT9) FAQ

What is the stock price today?

The current price is €7.50.

On which exchange is it traded?

Flight Centre Travel Group Ltd. is listed on NYSE.

What is its stock symbol?

The ticker symbol is AU000000FLT9.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Flight Centre Travel Group Ltd. ever had a stock split?

No, there has never been a stock split.

Flight Centre Travel Group Ltd. Profile

Software - Infrastructure Industry
Technology Sector
Mr. Ronald F. Clarke CEO
XSTU Exchange
US3390411052 ISIN
US Country
10,500 Employees
- Last Dividend
- Last Split
15 Dec 2010 IPO Date

Overview

FLEETCOR Technologies, Inc. is a prominent payments company that facilitates a wide range of expense management solutions for businesses and consumers, particularly those related to vehicle, lodging, and corporate payments. Having a global footprint, the company operates not only in the United States but also has a significant presence in Brazil, the United Kingdom, and other international markets. The company's operations are segmented into Vehicle Payments, Corporate Payments, Lodging Payments, and Others, demonstrating a diversified portfolio of payment solutions. Founded in 1986 and headquartered in Atlanta, Georgia, FLEETCOR has grown to become a key player in the payment solutions sector, serving a wide array of customers including businesses, merchants, consumers, and payment networks.

Products and Services

FLEETCOR Technologies, Inc. offers a comprehensive array of products and services tailored to meet the specific needs of their clients, ranging from vehicle payment solutions to corporate payment systems and beyond:

  • Vehicle Payment Solutions: These include a variety of services to manage expenses related to fuel, tolls, parking, fleet maintenance, and long-haul transportation. These solutions are designed to streamline the management of vehicle-related expenses for businesses.
  • Prepaid Food and Transportation Vouchers and Cards: FLEETCOR offers prepaid solutions to cover food and transportation expenses, providing an efficient way for businesses to manage these costs for their employees or customers.
  • Corporate Payment Solutions: This range includes a suite of products aimed at simplifying the corporate payments process, such as accounts payable automation, virtual cards, cross-border payments solutions, and purchasing as well as travel and entertainment card products. These solutions are crafted to enhance operational efficiencies in corporate financial transactions.
  • Lodging Payments Solutions: Tailored for employees traveling overnight for work, traveling crews, and stranded passengers from airlines and cruise lines, as well as insurance policyholders displaced from their homes due to damage or catastrophe, these solutions facilitate the simplification of managing lodging expenses under various circumstances.
  • Gifts and Payroll Cards: FLEETCOR also provides gift and payroll card products, offering an alternative and possibly more convenient method for businesses to distribute rewards or payroll to their employees.

Contact Information

Address: 3280 Peachtree Road
Phone: 770 449 0479